AbCellera Biologics
ABCL
169 hedge funds and large institutions have $809M invested in AbCellera Biologics in 2023 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 42 increasing their positions, 50 reducing their positions, and 48 closing their positions.
164% more call options, than puts
Call options by funds: $7.78M | Put options by funds: $2.94M
1.98% less ownership
Funds ownership: 45.19% → 43.21% (-2%)
8% less funds holding
Funds holding: 183 → 169 (-14)
16% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 50
17% less capital invested
Capital invested by funds: $980M → $809M (-$171M)
23% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 48
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$44.6M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$40.9M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$28M |
| 4 |
Millennium Management
New York
|
+$14.1M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$12.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$69.9M |
| 2 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$31M |
| 3 |
State Street
Boston,
Massachusetts
|
-$21.4M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$13.1M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$10.8M |
ABCL Hedge Fund Activity: Q2 2023 in Review
169 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q2 2023, worth a combined $809M — down 17% from $980M a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of ABCL and 37 opened new positions — a net loss of 11 holders — while 50 trimmed existing stakes and 42 added.
The largest buyer was Baillie Gifford & Co, adding an estimated $44.6M. The largest seller was BlackRock, cutting an estimated $69.9M.
- 169 institutional investors held AbCellera Biologics (ABCL) as of Q2 2023, down from 183 in Q1 2023.
- Funds reported $809M of AbCellera Biologics stock for Q2 2023, down 17% quarter-over-quarter.
- 37 funds opened new AbCellera Biologics positions in Q2 2023 and 48 closed out, a net change of -11 holders.
- The largest AbCellera Biologics buyer in Q2 2023 was Baillie Gifford & Co, an estimated $44.6M added.
- The largest AbCellera Biologics seller in Q2 2023 was BlackRock, an estimated $69.9M sold.
Based on aggregated 13F filings for Q2 2023.